Demographic and Treatment Characteristics of Patients Undergoing Transplantation of Allogeneic PBSCT or BM
| . | BMT . | PBSCT . | P Value* . |
|---|---|---|---|
| No. of patients | 62 | 29 | |
| Median age (range) [yrs] | |||
| Patients | 42 (24-58) | 42 (20-58) | NS |
| Donors | 38 (9-63) | 52 (18-66) | <.0005 |
| Donor → recipient gender† | |||
| F → F | 16 (26) | 6 (21) | |
| M → M | 18 (29) | 10 (34) | NS |
| M → F | 10 (16) | 5 (17) | |
| F → M | 18 (29) | 8 (28) | |
| Donor type† | |||
| HLA-identical sibling donor | 51 (82) | 16 (55) | <.01 |
| Partially HLA-matched family donor | 11 (18) | 13 (45) | |
| Median time interval (range) between diagnosis and transplant (mos) | 18 (1-42) | 19 (5-53) | NS |
| Interferon-α pretransplant† | 29 (47) | 16 (55) | NS |
| Median graft size (range) | |||
| Nucleated cell dose (×108/kg) | 3.1 (1.0-19.9) | 9.1 (4.1-27.8) | <.0001 |
| CD34+ cell dose (×108/kg) | 3.4 (1.2-9.7) | 9.5 (3.4-25.5) | <.0001 |
| GVHD prophylaxis† | |||
| Short methotrexate + cyclosporine | 62 (100) | 29 (100) | NS |
| Myeloablative regimen† | |||
| TBI + cyclophosphamide | 58 (94) | 27 (93) | NS |
| Busulfan + cyclophosphamide | 4 (6) | 2 (7) | |
| Median follow-up (range) of survivors (mos) | 28 (6-55) | 28 (6-55) | NS |
| . | BMT . | PBSCT . | P Value* . |
|---|---|---|---|
| No. of patients | 62 | 29 | |
| Median age (range) [yrs] | |||
| Patients | 42 (24-58) | 42 (20-58) | NS |
| Donors | 38 (9-63) | 52 (18-66) | <.0005 |
| Donor → recipient gender† | |||
| F → F | 16 (26) | 6 (21) | |
| M → M | 18 (29) | 10 (34) | NS |
| M → F | 10 (16) | 5 (17) | |
| F → M | 18 (29) | 8 (28) | |
| Donor type† | |||
| HLA-identical sibling donor | 51 (82) | 16 (55) | <.01 |
| Partially HLA-matched family donor | 11 (18) | 13 (45) | |
| Median time interval (range) between diagnosis and transplant (mos) | 18 (1-42) | 19 (5-53) | NS |
| Interferon-α pretransplant† | 29 (47) | 16 (55) | NS |
| Median graft size (range) | |||
| Nucleated cell dose (×108/kg) | 3.1 (1.0-19.9) | 9.1 (4.1-27.8) | <.0001 |
| CD34+ cell dose (×108/kg) | 3.4 (1.2-9.7) | 9.5 (3.4-25.5) | <.0001 |
| GVHD prophylaxis† | |||
| Short methotrexate + cyclosporine | 62 (100) | 29 (100) | NS |
| Myeloablative regimen† | |||
| TBI + cyclophosphamide | 58 (94) | 27 (93) | NS |
| Busulfan + cyclophosphamide | 4 (6) | 2 (7) | |
| Median follow-up (range) of survivors (mos) | 28 (6-55) | 28 (6-55) | NS |